Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 7/20 | 0.71 |
| ▸ | HTR1A | P08908 | 4/20 | 0.56 |
| ▸ | HTR7 | P34969 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | DRD2 | P14416 | 3/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6359138 | 1.00 | DRD4 (0.71) | DRD4HTR1AHTR7KCNH2DRD2 | |
| SCHEMBL6359232 | 0.87 | HTR1A (0.70) | DRD4HTR1ADRD2HTR2A | |
| SCHEMBL6359231 | 0.87 | HTR1A (0.70) | DRD4HTR1ADRD2HTR2A | |
| SCHEMBL6350236 | 0.85 | DRD4 (0.77) | DRD4HTR1AKCNH2DRD2 | |
| SCHEMBL6350240 | 0.85 | DRD4 (0.77) | DRD4HTR1AKCNH2DRD2 | |
| SCHEMBL10911267 | 0.84 | SIGMAR1 (0.53) | DRD4HTR1AHTR7KCNH2DRD2 | |
| SCHEMBL10911279 | 0.83 | SIGMAR1 (0.52) | DRD4HTR1AHTR7KCNH2DRD2 | |
| SCHEMBL6349954 | 0.83 | DRD4 (1.00) | DRD4HTR1AHTR7DRD2SIGMAR1 | |
| SCHEMBL6349951 | 0.83 | DRD4 (1.00) | DRD4HTR1AHTR7DRD2SIGMAR1 | |
| SCHEMBL6352815 | 0.83 | DRD4 (1.00) | DRD4HTR1AHTR7DRD2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050176727-A1 | Oximes and hydrazones that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176727-A1 | Oximes and hydrazones that are useful in treating sexual dysfunction | CYP19A1, SHBG, CYP17A1 | DRD4 1272/4885HTR1A 871/4885HTR7 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.